osteolabs partners with Swiss laboratory to deploy calcium isotope breakthrough
German biotech company osteolabs GmbH has secured a pivotal distribution partnership with leading Swiss medical laboratory ‘labor team’, bringing cutting-edge calcium isotope technology to Switzerland and Liechtenstein’s healthcare systems and with the aim of transforming bone health diagnostics for over half a million patients.
Isotope markers unlock early osteoporosis detection
The collaboration centres on osteolabs’ innovative OsteoTest platform, which harnesses proprietary Calcium Isotope Marker (CIM) technology to address critical gaps in bone health assessment. This sophisticated diagnostic approach enables real-time monitoring of Bone Calcium Balance (BCaB), capturing transient metabolic changes that traditional methods cannot reliably detect.
Clinical validation studies have revealed compelling correlations between CIM signatures and multiple metabolic disorders impacting musculoskeletal health, establishing the technology as a significant advancement in precision bone medicine.
Addressing substantial clinical need
Switzerland presents a considerable target market, with osteoporosis affecting a substantial patient population. “We are excited to partner with labor team w ag, one of the leading medical laboratories in Switzerland and Liechtenstein, to make our CIM technology available to clinicians and patients in these regions,” said Dr Michael Lutz. “This partnership helps us bring our advanced calcium isotope technology to a broader market.”
Priv.-Doz. Dr Thomas Brinkmann, COO at labor team, and Prof. Dr Guido Funke, CMO at labor team, added: “We are proud to integrate osteolabs’ pioneering OsteoTest into our diagnostic service offering. This test equips physicians with a powerful tool for early risk assessment and therapeutic monitoring of osteoporotic patients. According to the SVGO, over 500,000 patients in Switzerland .
